Tamer Soliman/iStock via Getty Images
4D Molecular Therapeutics (NASDAQ:FDMT) and the U.S. FDA have reached agreement on a phase 3 trial design for diabetic macular edema (DME) candidate 4D-150.
The company will only have to conduct a single pivotal trial due to data from 4D-150
